School of Medicine
Showing 471-480 of 638 Results
-
Lei (Stanley) Qi
Associate Professor of Bioengineering
BioDr. Lei (Stanley) Qi is Associate Professor of Bioengineering, Sarafan ChEM-H, and a Chan Zuckerberg Biohub Investigator. Dr. Qi is a principal contributor to the development of CRISPR technologies for genome engineering beyond gene editing. His lab created the first nuclease-deactivated Cas9 (dCas9) for targeted gene regulation in cells. His lab has invented a CRISPR toolbox for engineering the epigenome, including CRISPRi and CRISPRa for targeted gene repression and activation, epigenome editing, LiveFISH for real-time DNA/RNA imaging, CRISPR-GO for 3D genome manipulation, CasMINI as a compact CRISPR system for gene therapy, hyperCas12a for multi-gene engineering, and CRISPR antivirals aimed at treating broad RNA viruses.
Dr. Qi obtained B.S. in Physics and Math from Tsinghua University in 2005, and Ph.D. in Bioengineering from the University of California, Berkeley in 2012. He was a Systems Biology Faculty Fellow at UCSF between 2012-2014, and joined Stanford faculty in 2014. His research focuses on mammalian synthetic biology, epigenetic engineering, immune cell engineering, directed evolution, and novel approaches for gene therapy. -
Stephen Quake
Lee Otterson Professor in the School of Engineering and Professor of Bioengineering, of Applied Physics and, by courtesy, of Physics
Current Research and Scholarly InterestsSingle molecule biophysics, precision force measurement, micro and nano fabrication with soft materials, integrated microfluidics and large scale biological automation.
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team assesses approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program. -
Kavitha Ramchandran
Clinical Professor, Medicine - Oncology
Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.
In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs. -
Jianghong Rao
Professor of Radiology (Molecular Imaging Program at Stanford) and, by courtesy, of Chemistry
Current Research and Scholarly InterestsProbe chemistry and nanotechnology for molecular imaging and diagnostics
